FDA Approval Alert: The Need-to-Know | Three-Month Leuprolide Mesylate Formulation in Advanced Prostate Cancer

In August 2025, the FDA approved a leuprolide mesylate 3-month acting injectable formulation for patients with advanced prostate cancer.

FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
Article
Aug 29, 2025 2:00 PM
Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.